Cobos-Puc Luis E, Villalón Carlos M, Sánchez-López Araceli, Lozano-Cuenca Jair, Pertz Heinz H, Görnemann Tilo, Centurión David
Departamento de Farmacobiología, Cinvestav-Coapa, Czda. de los Tenorios 235, Col. Granjas-Coapa, Deleg. Tlalpan, C.P. 14330, México D.F., México.
Eur J Pharmacol. 2007 Jan 12;554(2-3):205-11. doi: 10.1016/j.ejphar.2006.09.068. Epub 2006 Oct 18.
It has been suggested that the alpha(2)-adrenoceptors mediating cardiac sympatho-inhibition in pithed rats closely resemble the pharmacological profile of the alpha(2A)-adrenoceptor subtype. However, several lines of evidence suggest that more than one subtype may be involved. Thus, the present study has pharmacologically re-evaluated the receptor subtype(s) involved in the inhibitory effect of the alpha(2)-adrenoceptor agonist, B-HT 933, on the tachycardic responses elicited by selective cardiac sympathetic stimulation (0.03, 0.1, 0.3, 1 and 3 Hz) in desipramine-pretreated pithed rats. I.v. continuous infusions of B-HT 933 (30 microg/kg min), which failed to modify the tachycardic responses to exogenous noradrenaline, inhibited those induced by preganglionic (C(7)-T(1)) stimulation of the cardiac sympathetic outflow at all frequencies of stimulation (0.03-3 Hz). This cardiac sympatho-inhibitory response to B-HT 933 was: (1) unaltered by saline (1 ml/kg) or the antagonists BRL44408 (100 microg/kg; alpha(2A)) or imiloxan (3000 and 10,000 microg/kg; alpha(2B)); (2) partially antagonized by BRL44408 (300 microg/kg) or MK912 (10 microg/kg; alpha(2C)) given separately; and (3) completely antagonized by rauwolscine (300 microg/kg; alpha(2)), MK912 (30 microg/kg) or the combination of BRL44408 (300 microg/kg) plus MK912 (10 microg/kg). Moreover, the above doses of antagonists, which are high enough to block their respective receptors, failed to block per se the tachycardic responses to sympathetic stimulation. These results suggest that the cardiac sympatho-inhibition induced by B-HT 933 in pithed rats is mainly mediated by stimulation of alpha(2A)- and alpha(2C)-adrenoceptors.
有人提出,在脊髓横断大鼠中介导心脏交感神经抑制的α(2)-肾上腺素能受体与α(2A)-肾上腺素能受体亚型的药理学特征极为相似。然而,有几条证据表明可能涉及不止一种亚型。因此,本研究从药理学角度重新评估了α(2)-肾上腺素能受体激动剂B-HT 933对去甲丙咪嗪预处理的脊髓横断大鼠中选择性心脏交感神经刺激(0.03、0.1、0.3、1和3 Hz)所引发的心动过速反应的抑制作用中涉及的受体亚型。静脉持续输注B-HT 933(30微克/千克·分钟),该剂量未能改变对外源性去甲肾上腺素的心动过速反应,却抑制了在所有刺激频率(0.03 - 3 Hz)下由心脏交感神经传出纤维的节前(C(7)-T(1))刺激所诱发的反应。B-HT 933对心脏交感神经的这种抑制反应:(1)不受生理盐水(1毫升/千克)或拮抗剂BRL44408(100微克/千克;α(2A))或咪洛昔生(3000和10000微克/千克;α(2B))的影响;(2)分别给予BRL44408(300微克/千克)或MK912(10微克/千克;α(2C))时部分被拮抗;(3)被萝芙木碱(300微克/千克;α(2))、MK912(30微克/千克)或BRL44408(300微克/千克)加MK912(10微克/千克)的组合完全拮抗。此外,上述足以阻断其各自受体的拮抗剂剂量本身未能阻断对交感神经刺激的心动过速反应。这些结果表明,B-HT 933在脊髓横断大鼠中诱导的心脏交感神经抑制主要是由α(2A)-和α(2C)-肾上腺素能受体的刺激介导的。